清眩补肾汤治疗原发性高血压疗效及对患者肾素-血管紧张素-醛固酮影响

目的:观察清眩补肾汤对原发性高血压患者肾素-血管紧张素-醛固酮系统的作用。方法:采用前瞻性随机临床研究方法,将150例符合标准的患者随机分为对照组75例,治疗组75例。对照组口服苯磺酸氨氯地平片,治疗组在对照组基础上加用清眩补肾汤。通过比较动态血压变化情况和血管紧张素、肾素、醛固酮指标以及用药安全性的检测进行疗效和安全性评定。结果:与对照组比较,治疗组能明显降低患者各时段血压N-SBP:(118.42±6.49)mmHg、(127.37±7.43)mmHg; D-DBP:(76.31±5.83)mmHg、(82.57±6.32)mmHg; 24-SBP:(121.23±6.31)mmHg、(129.56±7.57)mmHg;24-DBP:(73.22±5.34)mmHg、(79.46±6.54)mmHg,差异具有统计学意义(P<0.05)。同时能够降低高血压患者血管紧张素、肾素、醛固酮指标[AngⅡ(ng/L):51.93±12.39 vs. 79.33±14.26; Renin(pg/ml):5.26±1.31 vs. 7.32±1.57; ALD (ng/L):138.42±26.48 vs. 177.38±29.67,P<0.05]。比较两组患者治疗后用药安全性,肾功(UREA、Cr)、肝功(ALT、AST)情况无明显不良影响(P>0.05)。结论:清眩补肾汤可安全有效的通过抑制原发性高血压患者RAAS水平,进而降低血压水平。

Effect of Qingxuan Bushen decoction on renin-angiotensin-aldosterone system of primary hypertension patients

Objective:To observe the effect of Qingxuan Bushen decoction on the rennin-angiotensin-aldosterone system with primary hypertension patients.Methods:150 patients were randomizing divided into control group (n=75) and treatment group (n=75).The control group was received 5 mg amlodipine besylate,the treatment group on the basis of treatment in the control group plus the Qingxuan Bushen decoction.The blood pressure change and index of angiotensin,renin and aldosterone of primary hypertension patients were used as evaluating curative effect,meanwhile liver and renal function were assessed the drug safety.Result:4 weeks of treatment,the blood pressure of hypertension patients can be reduced N-SBP:(118.42±6.49)mmHg,(127.37±7.43) mmHg, D-DBP (76.31±5.83)mmHg,(82.57±6.32)mmHg, 24-SBP:(121.23±6.31)mmHg,(129.56±7.57)mmHg,24-DBP(73.22±5.34)mmHg ,(79.46±6.54)mmHg(P<0.05).The index of renin,angiotensin and aldosterone of primary hypertension patients also can be declined[AngⅡ(ng/L):51.93±12.39 vs.79.33±14.26,Renin(pg/ml):5.26±1.31 vs.7.32±1.57,ALD (ng/L):138.42±26.48 vs.177.38±29.67, P <0.05)].The liver and renal function were normal after using drug (P >0.05).Conclusion:Qingxuan Jiangya decoction can effectively and safely reduce the blood pressure with primary hypertension patients by regulating the renin-angiotensin-aldosterone system.